
IMCR
Immunocore Holdings PLC
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
34.610
Open
33.890
VWAP
--
Vol
312.39K
Mkt Cap
1.68B
Low
33.025
Amount
--
EV/EBITDA(TTM)
--
Total Shares
50.01M
EV
1.26B
EV/OCF(TTM)
40.47
P/S(TTM)
5.21
Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs Against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a clinical-stage pipeline of wholly owned and partnered programs across three different therapeutic areas: oncology, infectious diseases, and autoimmune and inflammation diseases. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, lung, gastric and others.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
97.96M
+16.55%
-0.259
-44.93%
96.73M
+20.54%
-0.197
-216.11%
93.14M
+23.52%
-0.162
-29.5%
Estimates Revision
The market is revising Upward the revenue expectations for Immunocore Holdings plc (IMCR) for FY2025, with the revenue forecasts being adjusted by 5.18% over the past three months. During the same period, the stock price has changed by 11.30%.
Revenue Estimates for FY2025
Revise Upward

+5.18%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward

-57.96%
In Past 3 Month
Stock Price
Go Up

+11.30%
In Past 3 Month
8 Analyst Rating

99.25% Upside
Wall Street analysts forecast IMCR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMCR is 66.75 USD with a low forecast of 33.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
1 Hold
0 Sell
Strong Buy

99.25% Upside
Current: 33.500

Low
33.00
Averages
66.75
High
100.00

99.25% Upside
Current: 33.500

Low
33.00
Averages
66.75
High
100.00
Deutsche Bank
initiated
$65
2025-05-27
Reason
Deutsche Bank
Price Target
$65
2025-05-27
initiated
Reason
Deutsche Bank initiated coverage of Immunocore with a Buy rating and $65 price target. The firm says Kimmtrak has established itself as the standard of care for HLA-A*02+ front-line metastatic uveal melanoma with its overall survival benefit. Immunocore's current valuation offers a favorable risk/reward where Kimmtrak's "niche" in metastatic uveal melanoma provides a "floor valuation" with expansion into second-line cutaneous melanoma providing upside, the analyst tells investors in a research note.
Oppenheimer
Oppenheimer
Outperform
maintain
$85 -> $86
2025-05-08
Reason
Oppenheimer
Oppenheimer
Price Target
$85 -> $86
2025-05-08
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on Immunocore to $86 from $85 and keeps an Outperform rating on the shares. The firm notes that on Wednesday, the company announced strong Q1 sales for KIMMTRAK, with revenue of $93.9M vs. OPCO/Consensus of $88M/$87M, +12% from the prior quarter.
JP Morgan
Jessica Fye
Buy
Maintains
$54 → $50
2025-04-14
Reason
JP Morgan
Jessica Fye
Price Target
$54 → $50
2025-04-14
Maintains
Buy
Reason
Needham
Gil Blum
Strong Buy
Reiterates
$71
2025-04-10
Reason
Needham
Gil Blum
Price Target
$71
2025-04-10
Reiterates
Strong Buy
Reason
Mizuho
Graig Suvannavejh
Hold
Maintains
$38 → $33
2025-04-07
Reason
Mizuho
Graig Suvannavejh
Price Target
$38 → $33
2025-04-07
Maintains
Hold
Reason
Mizuho lowered the firm's price target on Immunocore to $33 from $38 and keeps a Neutral rating on the shares. The firm's thesis on Immunocore remains unchanged, and while Mizuho views Immunocre as a pioneer and leader in the development of T-cell receptor-based therapeutics for cancer, overall lack of meaningful clinical newsflow over the next 12-15 months for the company makes it difficult to see why its shares should outperform.
HC Wainwright & Co.
Patrick Trucchio
Strong Buy
Reiterates
$100
2025-03-12
Reason
HC Wainwright & Co.
Patrick Trucchio
Price Target
$100
2025-03-12
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Immunocore Holdings PLC (IMCR.O) is -44.63, compared to its 5-year average forward P/E of -44.81. For a more detailed relative valuation and DCF analysis to assess Immunocore Holdings PLC 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-44.81
Current PE
-44.63
Overvalued PE
19.89
Undervalued PE
-109.51
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-60.37
Current EV/EBITDA
-18.66
Overvalued EV/EBITDA
82.78
Undervalued EV/EBITDA
-203.51
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair
5Y Average PS
16.50
Current PS
4.56
Overvalued PS
32.42
Undervalued PS
0.57
Financials
Annual
Quarterly
FY2025Q1
YoY :
+33.16%
93.88M
Total Revenue
FY2025Q1
YoY :
-86.35%
-3.62M
Operating Profit
FY2025Q1
YoY :
-120.56%
5.02M
Net Income after Tax
FY2025Q1
YoY :
-120.41%
0.10
EPS - Diluted
FY2025Q1
YoY :
-102.73%
137.00K
Free Cash Flow
FY2025Q1
YoY :
-0.54%
99.11
Gross Profit Margin - %
FY2025Q1
YoY :
-237.74%
7.81
FCF Margin - %
FY2025Q1
YoY :
-115.44%
5.35
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
1
24.0M
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
4
2.4M
Volume
Months
6-9
2
1.8M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
1
24.0M
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
IMCR News & Events
Events Timeline
2025-05-07 (ET)
2025-05-07
07:15:39
Immunocore reports Q1 EPS 10c, consensus (40c)

2025-02-26 (ET)
2025-02-26
07:09:21
Immunocore reports Q4 EPS (47c), consensus (16c)

2025-01-10 (ET)
2025-01-10
06:25:33
Immunocore reports cash, equivalents of $820M as of December 31

Sign Up For More Events
Sign Up For More Events
News
7.5
06-30GlobenewswireEr-Kim Announces Exclusive Agreement with Immunocore to Distribute KIMMTRAK in Turkey, and the MENA, Caucasus and CIS Regions
9.0
06-23NASDAQ.COMFDA Extends INCY's Application for Opzelura Label Expansion
8.5
06-20NASDAQ.COMCureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech
Sign Up For More News
People Also Watch

KSS
Kohls Corp
11.370
USD
-2.74%

HLIT
Harmonic Inc
8.990
USD
+3.10%

UMH
UMH Properties Inc
16.340
USD
-2.16%

DYN
Dyne Therapeutics Inc
9.910
USD
+7.72%

VRDN
Viridian Therapeutics Inc
17.800
USD
+6.02%

LNN
Lindsay Corp
135.700
USD
-0.83%

SFL
SFL Corporation Ltd
9.340
USD
-1.48%

UTI
Universal Technical Institute Inc
31.850
USD
+0.89%

GSBD
Goldman Sachs BDC Inc
11.360
USD
-1.73%

SCL
Stepan Co
49.900
USD
-9.67%
FAQ

What is Immunocore Holdings PLC (IMCR) stock price today?
The current price of IMCR is 33.5 USD — it has decreased -1.21 % in the last trading day.

What is Immunocore Holdings PLC (IMCR)'s business?

What is the price predicton of IMCR Stock?

What is Immunocore Holdings PLC (IMCR)'s revenue for the last quarter?

What is Immunocore Holdings PLC (IMCR)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Immunocore Holdings PLC (IMCR)'s fundamentals?

How many employees does Immunocore Holdings PLC (IMCR). have?
